NRNP 6675 Final Exam Prep Document | 2026/2027 Edition |
200 Verified Questions - 178 Questions with Answers
NRNP 6675 Final Exam 2026-178 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for graduate nursing
students enrolled in NRNP 6675, focusing on the advanced practice psychiatric mental health
curriculum. It contains 200 verified questions with detailed rationales, ensuring a thorough
understanding of key concepts. Updated for the 2026/2027 academic year, this resource aligns with the
latest evidence-based practices and national guidelines. Each question is crafted to mirror the format
and difficulty of the actual final exam, providing an authentic practice experience. With a focus on
clinical application and critical thinking, this document is an essential tool for achieving a top score.
Key Features:
Psychiatric assessment and differential diagnosis
Pharmacological management of psychiatric disorders
Psychotherapeutic interventions and modalities
Ethical and legal considerations in psychiatric nursing
Crisis intervention and suicide risk assessment
Integration of evidence-based practice in clinical scenarios
Updates for 2026:
- Revised to include 2026-2027 DSM-5-TR updates
- Added new questions on telehealth and digital mental health
- Updated pharmacological guidelines to reflect latest FDA approvals
- Enhanced rationales with clinical pearls and common pitfalls
- Aligned with the latest AACN Essentials and NONPF competencies
Abstract:
This exam preparation document for NRNP 6675 provides a rigorous and comprehensive review of advanced
psychiatric mental health nursing. The 200 questions are systematically organized to cover all major content
areas, including neurobiology, psychopharmacology, psychotherapy, and complex patient management. Each
question is accompanied by a detailed rationale that explains the correct answer and why the distractors are
incorrect, fostering deep learning and clinical reasoning. The content reflects the most current evidence-based
practices, incorporating the latest research and guidelines. This resource is indispensable for students seeking to
excel in their final exam and transition into advanced practice roles. With a focus on application and synthesis, it
bridges theoretical knowledge and real-world clinical scenarios. The document is structured to facilitate both
initial learning and last-minute review, ensuring confidence and competence on exam day.
Keywords:
NRNP 6675, Psychiatric Mental Health, Final Exam Prep, Verified Questions, 2026/2027, Advanced Practice
Nursing, Pharmacology, Psychotherapy
Answer Format:
Each question is presented in multiple-choice format with four options. Following each question, a comprehensive
explanation is provided, detailing the correct answer and the rationale behind it. Additionally, each distractor is
analyzed to clarify why it is incorrect, enhancing understanding of common misconceptions. The rationales are
written in a scholarly tone, referencing evidence-based sources and clinical guidelines.
Compliance Checklist:
Page 1
, Aligned with the latest DSM-5-TR criteria
Incorporates current AACN Essentials and NONPF competencies
Reflects 2026-2027 clinical practice guidelines
Includes ethical and legal standards for psychiatric nursing
Covers all major psychiatric disorders and treatments
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Psychiatric 1-25 Therapeutic communication, patient 12.5%
Mental Health Nursing assessment, ethical principles, legal issues
Neurobiology and 26-60 Neurotransmitters, psychotropic 17.5%
Psychopharmacology medications, side effects, drug interactions
Psychiatric Disorders and 61-110 Mood disorders, anxiety disorders, psychotic 25%
Differential Diagnosis disorders, personality disorders
Psychotherapy and Psychosocial 111-150 CBT, DBT, psychodynamic therapy, group 20%
Interventions therapy, family therapy
Special Populations and Crisis 151-175 Child and adolescent psychiatry, geriatric 12.5%
Management psychiatry, substance use disorders, crisis
intervention
Advanced Practice Role and 176-200 Collaborative care, telehealth, quality 12.5%
Healthcare Delivery improvement, evidence-based practice
Page 2
,Q1. A patient with treatment-resistant depression has failed adequate trials of two
SSRIs and one SNRI. Which augmentation strategy is most supported by current
evidence for rapid response?
A. Adding aripiprazole at 2 mg daily
B. Adding lithium carbonate titrated to serum level 0.6-0.8 mEq/L
C. Adding triiodothyronine (T3) at 25 mcg daily
D. Adding a second-generation antipsychotic at low dose
Correct Answer: A. Adding aripiprazole at 2 mg daily
Rationale: Aripiprazole is FDA-approved and has robust evidence for augmentation in
treatment-resistant depression, with response often seen within 1-2 weeks. Lithium is
effective but requires monitoring and slower titration. T3 has modest evidence, and
low-dose SGA augmentation is less specific.
Why Wrong:
B - Lithium augmentation is effective but has a slower onset and requires serum
monitoring, making it less ideal for rapid response.
C - T3 augmentation is an option but evidence for rapid response is weaker compared
to aripiprazole.
D - Low-dose SGA augmentation is a valid strategy but aripiprazole has the strongest
evidence for rapid response.
Reference: American Psychiatric Association. (2023). Practice Guideline for the
Treatment of Patients with Major Depressive Disorder.
Q2. Which of the following best explains why clozapine is reserved for
treatment-resistant schizophrenia despite its efficacy?
A. It has a higher risk of extrapyramidal symptoms compared to other antipsychotics
B. It requires mandatory hematologic monitoring due to risk of agranulocytosis
C. It is less effective than first-generation antipsychotics for negative symptoms
D. It has a higher risk of hyperprolactinemia and sexual dysfunction
Correct Answer: B. It requires mandatory hematologic monitoring due to risk of
agranulocytosis
Rationale: Clozapine is uniquely effective for treatment-resistant schizophrenia but
carries a 1-2% risk of agranulocytosis, necessitating strict monitoring of absolute
neutrophil count (ANC). This monitoring burden and potential fatality limit its use to
refractory cases.
Why Wrong:
A - Clozapine actually has a lower risk of EPS compared to typical antipsychotics.
C - Clozapine is at least as effective as other antipsychotics for negative symptoms,
often more so.
D - Clozapine is less likely to cause hyperprolactinemia than risperidone or typical
Page 3
, antipsychotics.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 30.
Q3. A patient with bipolar I disorder is euthymic and currently on lithium. Which
laboratory parameter requires the longest interval between routine checks?
A. Serum lithium level
B. Thyroid-stimulating hormone (TSH)
C. Serum creatinine
D. Calcium level
Correct Answer: D. Calcium level
Rationale: Lithium can affect renal and thyroid function, so creatinine and TSH are
typically checked every 6-12 months. Serum lithium is checked more frequently. Calcium is
not routinely monitored unless symptoms of hyperparathyroidism arise, making it the least
frequent.
Why Wrong:
A - Serum lithium levels are checked regularly (e.g., every 3-6 months or when
clinically indicated).
B - TSH is recommended at least every 6 months due to lithium-induced
hypothyroidism.
C - Creatinine is monitored every 6-12 months to assess renal function.
Reference: Goodwin, G.M., et al. (2023). Evidence-based guidelines for treating bipolar
disorder. Journal of Psychopharmacology.
Q4. Which of the following is the most critical concern when prescribing fluoxetine to
a patient also taking warfarin?
A. Increased risk of bleeding due to CYP2C9 inhibition
B. Reduced anticoagulant effect due to enzyme induction
C. Risk of serotonin syndrome if combined with anticoagulants
D. Decreased fluoxetine metabolism leading to toxicity
Correct Answer: A. Increased risk of bleeding due to CYP2C9 inhibition
Rationale: Fluoxetine inhibits CYP2C9, the enzyme that metabolizes warfarin's active
S-enantiomer, leading to elevated warfarin levels and increased bleeding risk. This
interaction is well-documented and requires close INR monitoring.
Why Wrong:
B - Fluoxetine is not an enzyme inducer; it inhibits several CYP enzymes.
C - Serotonin syndrome is not a typical concern with warfarin; bleeding is the primary
risk.
D - Fluoxetine's own metabolism is affected by other drugs, but the concern here is
warfarin's metabolism.
Page 4
200 Verified Questions - 178 Questions with Answers
NRNP 6675 Final Exam 2026-178 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for graduate nursing
students enrolled in NRNP 6675, focusing on the advanced practice psychiatric mental health
curriculum. It contains 200 verified questions with detailed rationales, ensuring a thorough
understanding of key concepts. Updated for the 2026/2027 academic year, this resource aligns with the
latest evidence-based practices and national guidelines. Each question is crafted to mirror the format
and difficulty of the actual final exam, providing an authentic practice experience. With a focus on
clinical application and critical thinking, this document is an essential tool for achieving a top score.
Key Features:
Psychiatric assessment and differential diagnosis
Pharmacological management of psychiatric disorders
Psychotherapeutic interventions and modalities
Ethical and legal considerations in psychiatric nursing
Crisis intervention and suicide risk assessment
Integration of evidence-based practice in clinical scenarios
Updates for 2026:
- Revised to include 2026-2027 DSM-5-TR updates
- Added new questions on telehealth and digital mental health
- Updated pharmacological guidelines to reflect latest FDA approvals
- Enhanced rationales with clinical pearls and common pitfalls
- Aligned with the latest AACN Essentials and NONPF competencies
Abstract:
This exam preparation document for NRNP 6675 provides a rigorous and comprehensive review of advanced
psychiatric mental health nursing. The 200 questions are systematically organized to cover all major content
areas, including neurobiology, psychopharmacology, psychotherapy, and complex patient management. Each
question is accompanied by a detailed rationale that explains the correct answer and why the distractors are
incorrect, fostering deep learning and clinical reasoning. The content reflects the most current evidence-based
practices, incorporating the latest research and guidelines. This resource is indispensable for students seeking to
excel in their final exam and transition into advanced practice roles. With a focus on application and synthesis, it
bridges theoretical knowledge and real-world clinical scenarios. The document is structured to facilitate both
initial learning and last-minute review, ensuring confidence and competence on exam day.
Keywords:
NRNP 6675, Psychiatric Mental Health, Final Exam Prep, Verified Questions, 2026/2027, Advanced Practice
Nursing, Pharmacology, Psychotherapy
Answer Format:
Each question is presented in multiple-choice format with four options. Following each question, a comprehensive
explanation is provided, detailing the correct answer and the rationale behind it. Additionally, each distractor is
analyzed to clarify why it is incorrect, enhancing understanding of common misconceptions. The rationales are
written in a scholarly tone, referencing evidence-based sources and clinical guidelines.
Compliance Checklist:
Page 1
, Aligned with the latest DSM-5-TR criteria
Incorporates current AACN Essentials and NONPF competencies
Reflects 2026-2027 clinical practice guidelines
Includes ethical and legal standards for psychiatric nursing
Covers all major psychiatric disorders and treatments
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Psychiatric 1-25 Therapeutic communication, patient 12.5%
Mental Health Nursing assessment, ethical principles, legal issues
Neurobiology and 26-60 Neurotransmitters, psychotropic 17.5%
Psychopharmacology medications, side effects, drug interactions
Psychiatric Disorders and 61-110 Mood disorders, anxiety disorders, psychotic 25%
Differential Diagnosis disorders, personality disorders
Psychotherapy and Psychosocial 111-150 CBT, DBT, psychodynamic therapy, group 20%
Interventions therapy, family therapy
Special Populations and Crisis 151-175 Child and adolescent psychiatry, geriatric 12.5%
Management psychiatry, substance use disorders, crisis
intervention
Advanced Practice Role and 176-200 Collaborative care, telehealth, quality 12.5%
Healthcare Delivery improvement, evidence-based practice
Page 2
,Q1. A patient with treatment-resistant depression has failed adequate trials of two
SSRIs and one SNRI. Which augmentation strategy is most supported by current
evidence for rapid response?
A. Adding aripiprazole at 2 mg daily
B. Adding lithium carbonate titrated to serum level 0.6-0.8 mEq/L
C. Adding triiodothyronine (T3) at 25 mcg daily
D. Adding a second-generation antipsychotic at low dose
Correct Answer: A. Adding aripiprazole at 2 mg daily
Rationale: Aripiprazole is FDA-approved and has robust evidence for augmentation in
treatment-resistant depression, with response often seen within 1-2 weeks. Lithium is
effective but requires monitoring and slower titration. T3 has modest evidence, and
low-dose SGA augmentation is less specific.
Why Wrong:
B - Lithium augmentation is effective but has a slower onset and requires serum
monitoring, making it less ideal for rapid response.
C - T3 augmentation is an option but evidence for rapid response is weaker compared
to aripiprazole.
D - Low-dose SGA augmentation is a valid strategy but aripiprazole has the strongest
evidence for rapid response.
Reference: American Psychiatric Association. (2023). Practice Guideline for the
Treatment of Patients with Major Depressive Disorder.
Q2. Which of the following best explains why clozapine is reserved for
treatment-resistant schizophrenia despite its efficacy?
A. It has a higher risk of extrapyramidal symptoms compared to other antipsychotics
B. It requires mandatory hematologic monitoring due to risk of agranulocytosis
C. It is less effective than first-generation antipsychotics for negative symptoms
D. It has a higher risk of hyperprolactinemia and sexual dysfunction
Correct Answer: B. It requires mandatory hematologic monitoring due to risk of
agranulocytosis
Rationale: Clozapine is uniquely effective for treatment-resistant schizophrenia but
carries a 1-2% risk of agranulocytosis, necessitating strict monitoring of absolute
neutrophil count (ANC). This monitoring burden and potential fatality limit its use to
refractory cases.
Why Wrong:
A - Clozapine actually has a lower risk of EPS compared to typical antipsychotics.
C - Clozapine is at least as effective as other antipsychotics for negative symptoms,
often more so.
D - Clozapine is less likely to cause hyperprolactinemia than risperidone or typical
Page 3
, antipsychotics.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 30.
Q3. A patient with bipolar I disorder is euthymic and currently on lithium. Which
laboratory parameter requires the longest interval between routine checks?
A. Serum lithium level
B. Thyroid-stimulating hormone (TSH)
C. Serum creatinine
D. Calcium level
Correct Answer: D. Calcium level
Rationale: Lithium can affect renal and thyroid function, so creatinine and TSH are
typically checked every 6-12 months. Serum lithium is checked more frequently. Calcium is
not routinely monitored unless symptoms of hyperparathyroidism arise, making it the least
frequent.
Why Wrong:
A - Serum lithium levels are checked regularly (e.g., every 3-6 months or when
clinically indicated).
B - TSH is recommended at least every 6 months due to lithium-induced
hypothyroidism.
C - Creatinine is monitored every 6-12 months to assess renal function.
Reference: Goodwin, G.M., et al. (2023). Evidence-based guidelines for treating bipolar
disorder. Journal of Psychopharmacology.
Q4. Which of the following is the most critical concern when prescribing fluoxetine to
a patient also taking warfarin?
A. Increased risk of bleeding due to CYP2C9 inhibition
B. Reduced anticoagulant effect due to enzyme induction
C. Risk of serotonin syndrome if combined with anticoagulants
D. Decreased fluoxetine metabolism leading to toxicity
Correct Answer: A. Increased risk of bleeding due to CYP2C9 inhibition
Rationale: Fluoxetine inhibits CYP2C9, the enzyme that metabolizes warfarin's active
S-enantiomer, leading to elevated warfarin levels and increased bleeding risk. This
interaction is well-documented and requires close INR monitoring.
Why Wrong:
B - Fluoxetine is not an enzyme inducer; it inhibits several CYP enzymes.
C - Serotonin syndrome is not a typical concern with warfarin; bleeding is the primary
risk.
D - Fluoxetine's own metabolism is affected by other drugs, but the concern here is
warfarin's metabolism.
Page 4
